Prasko 2002.

Methods	Allocation: randomized. Blindning: double blind. Duration: 3 weeks.
Participants	Diagnosis: Major depressive disorder. DSM‐III‐R. Inclusion criteria: 20‐60 years, no seasonal pattern, at least 2 episodes of major depression in life time, and at least one episode during the last 2 years, at least one episode in another season, HDRS (21‐item) more than 20. Exclusion criteria: bipolar depression, panic disorder, alcoholism or drug abuse, antisocial or histrionic personality disorder, schizophrenia, organic brain impairment, mental retardation, physical illness or medical contranindications for imipramine, endocrine disease history, pregnancy, drugs causing depression during the past month, eye diseases. N = 34 (29 completers). Age: mean 42.6 years (completers). Sex: F 22, M 12. Setting: inpatients.
Interventions	1. Bright light (5000 lux 6‐8 AM) + imipramine 150 mg/day. N = 11. 2. Bright light (5000 lux 6‐8 AM) + imipramine‐like placebo. N = 9. 3. Dim red light (500 lux 6‐8 AM) + imipramine 150 mg/day. N = 9. Device: light box. Bright light device:
Outcomes	Mental state (HDRS ‐ 21‐item, MADRS, BDI). Global state (CGI).
Notes	Light adjunct to pharmacotherapy. Only interventions 1. and 3. compared.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear